# Clinical Trials Data EGFR - Document 20

# First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT01646450

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Recurrent or progressive Non-Small Cell Lung Cancer stage IV or IIIB patients.\n\* Positive EGFR Mutation.\n\* No previous systemic anticancer therapy.\n\* Male and female patients aged over 70 years.\n\* Measurable lesion according to RECIST with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site.\n\* Provision of written informed consent.\n\nExclusion Criteria:\n\n\* Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).\n\* Known severe hypersensitivity to icotinib or any of the excipients of this product.\n\* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "70 Years",  
"stdAges": [  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
A patient with an EGFR mutation \*could\* be eligible, but more information is needed. While having a positive EGFR mutation is an inclusion criterion, the patient must \*also\* meet all other inclusion criteria and \*not\* meet any exclusion criteria.  
  
Specifically, we need to know if the patient:  
  
\* \*\*Has recurrent or progressive NSCLC stage IV or IIIB:\*\* This is essential.  
\* \*\*Has received prior systemic anticancer therapy:\*\* If yes, they are excluded.  
\* \*\*Is over 70 years old:\*\* If younger than 70, they are excluded.  
\* \*\*Has a measurable lesion according to RECIST:\*\* This is a requirement for tracking treatment response.  
\* \*\*Has active interstitial lung disease or a hypersensitivity to icotinib:\*\* If yes, they are excluded.  
\* \*\*Has any other significant clinical disorder that makes participation undesirable:\*\* This requires a physician's evaluation.  
  
  
Therefore, simply having the EGFR mutation is not enough to determine eligibility.